By Clinical Research Team  

November 25, 2024 | GeneDx announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data—powered by GeneDx’s database—to improve all stages of drug development; Critical Path Institute announced a landmark initiative, Gender Equitable Medicines for Parkinson's Disease, dedicated to globally advancing actionable research on how Parkinson's disease uniquely impacts women and individuals across the sex and gender spectrum; and more. 

GeneDx announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data—powered by GeneDx’s database—to improve all stages of drug development. The new offering is part of GeneDx’s ongoing investment to deliver personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. GeneDx Discover is a self-service tool that leverages real-world data to enable a deeper understanding of the characteristics of target patient populations. The tool combines disease prevalence and phenotypic information, alongside variant-level details, unlocking a better understanding of the size and unique characteristics of the total addressable market for genetically-defined disease cohorts, as well as obtaining variant-level resolution to define the cohort. Press release. 

CapeStart debuted MadeAi, a generative AI-based platform that dramatically streamlines the synthesis of clinical information, with its first solution, MadeAi-LR. Supporting literature review, MadeAi-LR unlocks efficiency for systematic literature reviews (SLRs), clinical evidence reports (CERs), meta research, targeted literature reviews (TLRs), and other clinical literature assessments. MadeAi-LR cuts literature review time nearly in half—with 90% accuracy for title and abstract screening, and more than 80% accuracy for data extraction, and single- and multiple-article summarizations. Features of MadeI-LR include GenAI-aided screening, summarizing (including single-article summary and multiple-articles summary), and authoring; confidence scoring; full-text purchase and management; and more. Press release. 

Critical Path Institute (C-Path) announced a landmark initiative, Gender Equitable Medicines for Parkinson's Disease (GEM-PD), dedicated to globally advancing actionable research on how Parkinson's disease uniquely impacts women and individuals across the sex and gender spectrum. GEM-PD aims to accelerate the development of more personalized treatments by leveraging diverse data and innovative technologies, such as artificial intelligence and digital health technologies. The initiative seeks to generate drug development solutions that will lead to more equitable approaches to detection, disease management, and therapies for all individuals living with Parkinson's. GEM-PD will also partner with and build upon the achievements of C-Path's Critical Path for Parkinson's (CPP) Consortium, a global public-private partnership committed to accelerating the development of therapies that improve the lives of those with Parkinson's. Press release. 

Capitainer announced the establishment of an expansion in the U.S. named Capitainer Inc. This expansion will enhance customer service and streamline order processing for the company’s growing U.S. market, further strengthening Capitainer’s goal to become the global leader in self-sampling. As of September 1, all U.S. orders will be processed through Capitainer Inc., enabling the company to provide faster, more tailored service to North American clients. Capitainer’s expanded U.S. presence will improve delivery times, offer local support, and allow for better responsiveness to market needs. Press release. 

Stand Up To Cancer (SU2C) announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab, and daratumumab, to treat a rare disease called AL amyloidosis. Affecting approximately 4,500 people annually in the U.S., AL amyloidosis can be associated with blood cancers, particularly multiple myeloma as well as lymphomas or chronic lymphocytic leukemia. Press release. 

Medable announced Medable AI, generative AI capabilities that help sponsors and clinical research organizations (CROs) build digital and decentralized trials faster with complete visibility and control over technology setup. Medable is the first to incorporate generative AI in the study build process, ultimately driving the industry to a breakthrough, one-day study startup. Medable AI integrated in Medable Studio can automate repetitive, time-intensive manual tasks to decrease time to First Patient In (FPI) for digital and decentralized clinical trials, dramatically accelerating study startup. Building out multiple outcomes assessments for a study traditionally takes days but can now be completed in 30 minutes, based on early metrics. Press release. 

CCRM Nordic, Sahlgrenska Academy, and Sahlgrenska University Hospital formed a strategic partnership relating to promote and simplify cooperation within the field of advanced therapy medicinal products (ATMPs) and related technologies. The parties’ intention is that this partnership will be part of a broader focus to link the Swedish and Nordic ATMP ecosystems with research and development within academia, healthcare, and industry. The parties have agreed to explore opportunities for cooperation within project and business development, process development from early research to production, quality-controlled GMP production, making clinical trials possible, training, and knowledge exchange. Press release.